Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Intangibles (2017 - 2023)

Historic Intangibles for Aclaris Therapeutics (ACRS) over the last 7 years, with Q4 2023 value amounting to $751000.0.

  • Aclaris Therapeutics' Intangibles fell 8982.38% to $751000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $751000.0, marking a year-over-year decrease of 8982.38%. This contributed to the annual value of $751000.0 for FY2023, which is 8982.38% down from last year.
  • Aclaris Therapeutics' Intangibles amounted to $751000.0 in Q4 2023, which was down 8982.38% from $7.4 million recorded in Q3 2023.
  • Aclaris Therapeutics' 5-year Intangibles high stood at $73.8 million for Q1 2019, and its period low was $751000.0 during Q4 2023.
  • Over the past 5 years, Aclaris Therapeutics' median Intangibles value was $7.4 million (recorded in 2019), while the average stood at $13.7 million.
  • Its Intangibles has fluctuated over the past 5 years, first surged by 90936.94% in 2019, then plummeted by 8999.93% in 2020.
  • Quarter analysis of 5 years shows Aclaris Therapeutics' Intangibles stood at $7.4 million in 2019, then changed by 0.0% to $7.4 million in 2020, then changed by 0.0% to $7.4 million in 2021, then changed by 0.0% to $7.4 million in 2022, then crashed by 89.82% to $751000.0 in 2023.
  • Its Intangibles was $751000.0 in Q4 2023, compared to $7.4 million in Q3 2023 and $7.4 million in Q2 2023.